饮食中小分子的开发作为阿尔茨海默病多重向治疗策略
Rengasamy Balakrishnan1, Khoshnur Jannat2, Dong-Kug Choi1
1Department of Applied Life Sciences, Graduate School, BK21 Program, Konkuk University, Chungju, 27478, South Korea; Department of Biotechnology, College of Biomedical and Health Science, Research Institute of Inflammatory Disease (RID), Konkuk University, Chungju, 27478, South Korea.
饮食中的小分子显示出减缓衰老和阿尔茨海默病 (AD) 的认知衰退的前景. 这些通过纳米技术增强的天然化合物,提供了一种安全有效的神经保护方法,并对抗与年龄相关的认知障碍.
科学领域:
- 神经科学和衰老研究研究
- 营养科学和药理学 营养科学和药理学
背景情况:
- 认知功能障碍是正常衰老和神经退行性疾病 (如阿尔茨海默氏症) 的标志.
- 目前治疗阿尔茨海默病的疗法有效性有限,副作用很大,需要新的治疗策略.
- 使用营养保健品的饮食干预措施因其在预防或减轻AD症状方面的神经保护潜力而受到越来越多的关注.
研究的目的:
- 审查对饮食中的小分子及其成分用于阿尔茨海默氏症 (AD) 治疗的研究.
- 探索这些化合物的化学结构,有效剂量和分子作用机制.
- 讨论基于纳米技术的药物输送对增强AD治疗的好处.
主要方法:
- 关于饮食中小分子的临床和临床前研究的综合文献综述.
- 分析着重于黄类,胡卜素和多酸的研究.
- 探索纳米技术的应用,以提高这些药物的生物可用性和疗效.
主要成果:
- 饮食中的小分子调节关键的衰老机制:氧化应激,神经炎症,亡和自.
- 这些化合物可以改善认知障碍,线粒体功能障碍和肠道微生物群失调.
- 纳米技术显著提高了口服生物可用性,安全性和治疗效果,减少了不良影响.
结论:
- 饮食中的小分子具有重要的潜力,作为新的,安全的治疗剂,用于预防和治疗与年龄相关的认知衰退和AD.
- 对这些天然化合物和先进的输送系统进行进一步的研究是有必要的.
- 营养药物与纳米技术相结合,为管理阿尔茨海默病和在衰老过程中促进大脑健康提供了一个有希望的途径.
更多相关视频
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
相关概念视频
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Dementia
The progression of dementia is generally gradual....
